304.30

0.28% 0.91

Praxis Precision Medicines Inc (PRAX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$303.39

Aprire:

$298.5

Volume 24 ore:

146.10K

Relative Volume:

0.33

Capitalizzazione di mercato:

$8.48B

Reddito:

$7.46M

Utile/perdita netta:

$-326.53M

Rapporto P/E:

-22.74

EPS:

-13.3803

Flusso di cassa netto:

$-282.53M

1 W Prestazione:

+18.26%

1M Prestazione:

-11.45%

6M Prestazione:

+10.34%

1 anno Prestazione:

+630.80%

Intervallo 1D:

$296.36

$307.65

Intervallo di 1 settimana:

$259.08

$307.65

Portata 52W:

$37.19

$366.52

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Nome

Praxis Precision Medicines Inc

Settore

Healthcare (1109)

Industria

Biotechnology (619)

Telefono

617-300-8460

Indirizzo

99 HIGH STREET, 30TH FLOOR, BOSTON

Dipendente

10,998

Cinguettio

Prossima data di guadagno

2026-08-03

Ultimi documenti SEC

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PRAX Praxis Precision Medicines Inc	304.32	7.87B	7.46M	-326.53M	-282.53M	-13.38
VRTX Vertex Pharmaceuticals Inc	470.29	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	617.98	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	930.85	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	290.41	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	170.59	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-10	Iniziato	Raymond James	Strong Buy
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-02-02	Iniziato	Wells Fargo	Equal Weight
2025-12-15	Reiterato	Oppenheimer	Outperform
2025-11-19	Iniziato	BTIG Research	Buy
2025-06-02	Ripresa	Oppenheimer	Outperform
2025-05-07	Iniziato	Chardan Capital Markets	Buy
2025-03-03	Reiterato	H.C. Wainwright	Buy
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-08-05	Iniziato	Oppenheimer	Outperform
2024-06-24	Iniziato	Needham	Buy
2024-06-18	Iniziato	Guggenheim	Buy
2024-05-01	Iniziato	Robert W. Baird	Outperform
2023-09-19	Iniziato	Truist	Buy
2022-06-06	Downgrade	Wedbush	Outperform → Neutral
2021-12-16	Iniziato	H.C. Wainwright	Buy
2021-08-26	Iniziato	BofA Securities	Buy
2021-04-26	Iniziato	William Blair	Outperform
2020-11-11	Iniziato	Wedbush	Outperform
2020-11-10	Iniziato	Cowen	Outperform
2020-11-10	Iniziato	Evercore ISI	Outperform
2020-11-10	Iniziato	Piper Sandler	Overweight

Mostra tutto

Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie

Jun 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen (PRAX-222) in Pediatric SCN2A-DEE Seizures - Minichart

Jun 22, 2026

FDA grants breakthrough therapy status to Praxis’ elsunersen - Investing.com UK

Jun 22, 2026

Praxis Precision Medicines receives FDA breakthrough therapy designation for elsunersen - Investing.com Canada

Jun 22, 2026

Form 8K Praxis Precision Medicines Inc For: 22 June By Investing.com - Investing.com Canada

Jun 22, 2026

FDA Breakthrough Therapy nod for Praxis (PRAX) seizure drug elsunersen - Stock Titan

Jun 22, 2026

Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results - Benzinga

Jun 22, 2026

Praxis Precision Medicines (PRAX) Receives FDA Breakthrough Ther - GuruFocus

Jun 22, 2026

Praxis Precision (PRAX) Receives FDA Breakthrough Designation fo - GuruFocus

Jun 22, 2026

Praxis Precision Medicines Potential Epilepsy Treatment Receives US FDA Breakthrough Therapy Designation - Moomoo

Jun 22, 2026

Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation - Yahoo Finance

Jun 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - The Manila Times

Jun 22, 2026

Praxis Precision Medicines stock rises on FDA breakthrough status - Investing.com

Jun 22, 2026

FDA gives Praxis seizure drug Breakthrough Therapy status - Stock Titan

Jun 22, 2026

Jun 21, 2026

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits

Jun 21, 2026

Jun 19, 2026

Precision Trading with Praxis Precision Medicines Inc. (PRAX) Risk Zones - Stock Traders Daily

Jun 19, 2026

Analysts Offer Insights on Healthcare Companies: Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Jun 19, 2026

A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $162 to $1,201 - Moomoo

Jun 19, 2026

Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo

Jun 19, 2026

Jun 18, 2026

Praxis Precision Medicines StockAnalyst consensus and trading snapshot - AD HOC NEWS

Jun 18, 2026

PRAX Initiates Coverage On RBC Capital -- Price Target Set at $4 - GuruFocus

Jun 18, 2026

Praxis a new outperform at RBC on recent pullback - MSN

Jun 18, 2026